The Scientific Committee of the 2023 HealthPlus Fertility Conference invites abstracts from all scientists, physicians, nurses, and anyone interested in the field of reproductive medicine. The submission period begins on January 25, 2023, and closes on July 1, 2023, at 6:00 pm UAE time. We advise all submitters to read this guide before submitting an abstract. 

By submitting an abstract, the author(s) consent to present their work in person. 

Abstracts will be evaluated by the conference scientific committee. Authors are asked to indicate on the abstract submission form whether they prefer an oral or poster presentation. Abstracts submitted for oral/poster presentation but not selected for oral presentation may be referred to the poster sessions. Decisions of the selection committee are final. All accepted abstracts and the list of authors will be published in the conference brochure. 

All abstracts will be reviewed and evaluated and then accepted or rejected for presentation. This process will take some time and the result will be emailed to each author by July 15, 2023. 

  • Abstracts should be organized according to a series of subtitles:
  • Abstract Title: The title should reflect the content and should be no more than 20 words long 
  • Listing of Authors: The name of the first-named author is the presenting author. Do not include professional titles or degrees. 
  • Background: should not exceed 50 words. 
  • Methodology: should not exceed 150 words. 
  • Results: should not exceed 150 words. 
  • Discussion and Conclusions: should not exceed 150 words. 
  • Conflicts: Must declare any conflicts of interest or funding. 
  • Keywords: provide a minimum of two, and a maximum of five keywords. 
  • Please keep the following points in mind when submitting your abstract: 
  • Abstracts should be submitted in English only. 
  • Abbreviations may be used after they have been previously defined.

Topics of Abstract

  • Andrology (incl. male (in)fertility, spermatogenesis, diagnostic tests, treatment, MESA, TESA, TESE, sperm donation, lifestyle and environmental factors related to male fertility, immunology, male contraception, sperm selection and processing, intrauterine insemination, infectious and male infertility). 
  • Embryology (incl. IVF/ICSI, oocyte and embryo selection, culture, cryopreservation, developmental biology, quality control) 
  • Endometriosis, endometrium and fallopian tube, and benign disorders of the endometrium and fallopian tube
  • Ethics and law 
  • Implantation and early pregnancy (incl. miscarriage, recurrent miscarriages, termination of pregnancy, ectopic pregnancy, pregnancy of unknown location, gestational trophoblastic disease) 
  • Male and female fertility preservation (incl. medical indications, elective gamete freezing, laboratory techniques)
  • Psychology and counselling
  • Reproductive (epi)genetics (incl. (epi)genetic causes of infertility, PGD, PGS, prenatal diagnosis) 
  • Reproductive endocrinology (incl. ovarian reserve testing, ovarian stimulation, IVM, POI, PCOS, infancy, disorders of sexual development, puberty, adolescence, menopause) 
  • Reproductive epidemiology, socio-cultural aspects, and health economy (incl. cross border & developing countries)
  • Reproductive surgery (female and male) 
  • Safety and quality of ART therapies (incl. guidelines, accreditation, EUTCD, certification, complications: premature laboUr, malformations, neonatal risks, multiple pregnancy, long-term follow-up of children, imaging in ART) 
  • Stem cells (inc. pluripotent stem cells (ESC-iPSC), somatic nuclear transfer, use of stem cells in reproduction, mesenchymal stem cells, artificial gametes, spermatogonial stem cells, oogonia, organoids, differentiation, pluripotency, regenerative medicine, CRISPR/CAS) 
  • Nursing and midwifery